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g) once a day for 5 days, nine received placebo. At day 14, animals were sacrificed and 
angiogenesis analysed by counting vessels on histological sections. 
RESULTS (shown in the table below): CD 31 quantification pointed out a minimal anglo- 
genesis induced in control implants, significantly increased in bFGF implants, and sur- 
prisingly enhanced in bFGF+ASIS implants. However, TF inhibition significantly 
decreased the number of perfusad vessels, as shown by CD31 peffusad vessels quanti- 
fication and May Grunwald Giemsa quantification. 
CONCLUSION: TF inhibition does not inhibit bFGF-induced angiogenesis, but rather 
impairs neovasculadzation maturation, with a dramatical decrease of perfused bFGF- 
induced vessels. These results indicate the critical role of TF in post-natal non-tumorel 
angiogenesis. 
CD31 total CD31 perfused May Grunwald 
vessels vessels Giemsa 
control (n=5) 70+/20 64+/-13 42+/-27 
bFG F + placebo (n=9) 140+/-34 * 104+/-35 104+/-26 
bFGF+ ASIS (n=8) 182+/-66 * 59+/-9 "i" 56+/-16 1 
• P<0.0001 vs placebo. 1"P<0.0001 vs bFGF 
1008-75 A Growth Factor Mixture That Significantly Enhances 
Collateral Growth 
Wilfded Roethv, Eduard Fiehn, Kotaro Suehiro, Anguo Gu, Geng Hua Yi, Juichire 
Shimizu, Jie Wang, Geping Zhang, John Ranieri, Rama Akella, James Benedict, Daniel 
Burkhoff, Columbia Universi~ New York, New York, Sulzer Inc., Austin, Texas. 
Background: Studies of therapeutic angiogenesis have focused on use of single growth 
factors. However, angiogenesis is complex and multiple factors participate on the cas- 
cade. Moreover, recent publications have identified synergistic effects of angiogenic 
agents in the induction of vascular growth. We tested the efficacy of a naturally occurring 
growth factor mixture (GFm) isolated from bovine bones and previously shown to stimu- 
late angiogenesis more potently than single growth factors. 
Methods: Components of GFm (SDS-PAGE, mass spectrometry and Western blot) 
include transforming growth factor beta 1-3, bone morphogenic protein 2-7, and fibre- 
blast growth factor 1. To evaluate the angiogenic potential, a randomized, blinded, pla- 
cebo-controlled study was performed. An LAD amereid constrictor was placed in 21 dogs 
to create chronic ischemia. 3 weeks later, angiography confirmed ameroid closure and 
defined the degree of collateral filling of the distal LAD. Dogs were randomized into 3 
groups: GFml (1 mg/ml), GFmt0 (10 mg/ml) or placebo (P), each injected into ischemic 
myocardium (15-20 injections/heart, 0.15 ml/injection) via thoracotomy. Animals received 
bromodeoxyuddioe (BrdU) injections to label proliferating cells. 6 weeks later angiogra- 
phy studies were repeated. Hearts were removed and evaluated histologically. Histology 
and angiograms were graded with semiquantitative scales. Aft analyses were done 
blinded to treatment group. 
Results: Histologically, GFm dose dependently induced growth of large, BrdU positive 
vessels (vascular growth index: 0.2±0.2, 1.0±0.2, 1.7±0.2 in P, GFml and GFml0, 
respectively; p=0.001). Angiogrephically, opacification of the distal LAD significantly 
improved with GFm (distal LAD opacification score: 0,4±0.2, 1.1±0.14, 1.6±0.3 in P, 
GFm I and GFml0, respectively; p=0,014). 
Conclusion: GFm is a potent angiogenic agent that stimulates large vessel growth in 
chronically ischemic myocardium in a dose dependent manner, Collateral vessels devel- 
oped to the occluded LAD to significantly improve or completely reconstitute its visualiza- 
tion during contrast injection. 
1008-76 Trans-Epicardial Transplantation of Mature Endothelial 
Cells Induces Neoangiogenesis and Improves LV 
Function in an Animal Model of Ischemic 
Cardiomyopathy 
v. Chekanov, V. Nikolaychik, G. Tchekanov, G. Dangas, G. Roubin, M. B. Leon, J, W. 
Moses, Nicholas N. Kioshidze. Lenox Hill Heart and Vascular Institute, New York, New 
York, Heart Care Associates and Milwaukee Heart Institute, Milwaukee, Wisconsin. 
Objective: We hypothesize that transplantation of heterotepic mature endothelial cells 
(EC) within a fibrin platform would increase production of endogenous growth factors and 
promote development of a functional capillary network. The objective of this study was to 
investigate the effect of autologous EC transplantation using a fibrin meshwork on 
ischemic myocardium of sheep. 
Methods: Placing ameroid constrictors on the circumflex artery of 12 adult sheep pro- 
duced ischemic cardiomyopathy. Three groups were randomized (4 animals/greup) to 
transepicardial injection (3 sites/animal), 4 weeks after amereid placement: sham treat- 
ment (saline with denatured cells), controls (no injections), and EC fibrin meshwork 
(autologous mature EC, 5x105 per injection site, harvested from jugular veins). Eight 
weeks after trans-epicardial treatment animals were assessed for myocardial function 
(echo), myocardial flow, histology (capillary area) and myocardial ultrastructure (TEM). 
Results: Eight weeks after EC/sham/control treatment, EF was markedly improved in the 
EC transplant group (0.56+-0.04 p=0.029 versus baseline), whereas in the sham and 
control groups, EF deteriorated (0.40+-0.08 p= 0.013 Vs EC and 0.39+-0.05 p=0.0017 
Vs EC group respectively). Myocardial blood flow (ml/min/g) measured with colored 
microspheres was also significantly increased in the EC transplant group (0.66+-0.10 
versus 0.15+-0.03 in control and 0.18+-0.05 in saline group; p=0.0009 Vs control and 
p=0.0001 Vs saline). In the EC transplant zones, histology revealed extensive neovascu- 
larization (significant increase in capiflary area) and TEM demonstrated functional arteri- 
oles and cappilaries. 
Conclusion: Trans-epicardial heterotopic transplantation of EC within a fibrin matrix dra- 
matically enhances neovascularization, increases myocardial blood flow and improves 
LV function in an animal model of ischemic cardiomyopathy. The fibrin meshwork plat- 
form may serve as a generalized enhancement vehicle for other stem cell transplant 
methodologies to treat pts with refractory ischemia and/or LV dysfunction. 
1008-77 Long-Term Safety and Efficacy of Intramuscular 
Administration of  C1-1023 (AdGVVEGF121.10) in 
Patients With Intermittent Claudication 
San!av Ra!aeooalan, Jeffrey D. Trechtenberg, Jeffrey W. Olin, Emile R. Mohler, III, 
Raphael Pak, Angelo Secci, Scott McBride, Henrik Rasmussen, Ronald G. Crystal, 
University of Michigan, Ann Arbor, Michigan. 
Background. In a Phase I study, we evaluated the safety and efficacy of C1-1023 
(AdGvVEGF121.10, adenovirus encoding vascular endothelial growth factor121) in 
patients with advanced intermittent claudication (IC) secondary to SFNinfrageniculate 
disease. 
Methods: Patients were randomized to IM dosing of placebo (n=3) or C1-1023 (4 x 108 to 
4 x 101° particle units, n= 15). 
Results: 73% and 33% of C1-1023 and placebo patients respectively completed 1 year of 
follow-up. Edema and rash were the most common early adverse event with 47% of CI- 
1023 subjects developing edema (mild- moderate) in the injected extremity. One infra- 
inguinal bypass procedure occurred in the placebo and C1-1023 groups at day 29 and 
104 respectively. One death (day 160) and one malignancy (day 274) occurred in the CI- 
1023 group, none were judged related to C1-1023. Table 1 summarizes the median 
change in peak walking time (PW-F), claudication onset time (COT) and ankle brachial 
indices (ABI) for the C1-1023 group. 
30 days 90 days 180 days 360 days 
Rest ABI 0.04, 0.11 (14) 0.21", 0.13(6) 0.09*, 0.30 (12) 0.09", 0.06 (9) 
Stress ABI -0.06, 0.13 (7) 0.02, 0.06 (4) -0.09, 0.13 (6) -0.08, 0.10 (4) 
~COT 0.5,0.8(4) 0.2, 1.8(2) 0.1, 1.1 (3) 0.5, 0 (1) 
A PWT 1.0", 0.7 (8) 2.0, 5.0 (4) 2.0, 4.1 (7) 4.8, 5.5 (4) 
All values are Median, Inter-quartile range (75 th - 25 th percentile). Parenthesis = Number 
of patients with data at baseline and time point. * p < 0.05 by signed rank test 
The walking distance perception score in the walking impairment questionnaire showed 
an improvement at 30 days corresponding to the improvement in PWT. 
Conclusions: Administration of C1-1023 to IC patients was adequately tolerated and 
associated with an apparent improvement in clinical outcomes upto 1 year. Larger stud- 
ies with placebo controls in IC are ongoing. 
1008-78 Induct ion  o f  Angiogenesis by Metalloproteinase 
Der ived From Venom of Indian Cobra in a Mode l  o f  Rat 
Hind  L imb Ischemia 
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Shyarn S. Chauhan, Suruchi Chopra, Sanjiv Sharma, Rajiv Narang, Prem Chopra, Tej P, 
Singh, Subhash C. Manchaoda, All India Institute of Medical Sciences, New Delhi, India. 
Background: The field of therapeutic aogiogenesis has evolved from formation of capil- 
lary sprouts to development of arterial collaterals (arteriogenesis), One of the shortcom- 
ings of strategies designed solely to stimulate proliferation of endothelial cells (ECs) such 
as VEGF therapy, is the fact that only capillary (<40pro) networks are formed. Instead, 
formation of large conductance arterioles require a series of sequential steps involving 
EC migration, adhesion and differentiation and smooth muscle cell (SMC) migration. 
Venom from indian cobra contains several potent enzymes including metalloproteinases 
(MP). We undertook the present study to test efficacy of MP and phospholipase A2 (PLA- 
2) derived from venom of Indian cobra and compare it with plasmid VEGF 165 (ph VEGF 
165) gene. 
Methods : Male Wister albino rats (6 in each group) were randomized to receive MP lmg/ 
kg, PLA-2 2.Smg/kg, ph VEGF 165 400pg or normal saline (control), 2 days after left fem- 
oral artery division. Fifteen days after femoral artery division, digital subtraction angiogra- 
phy (DSA) was performed and muscles of thigh distal to the site of division subjected to 
histopathological examination. 
Results : On DSA there was a mild increase in number of large arterial collaterals both in 
MP and pH VEGF 165 groups as compared to PLA.2 or saline groups (statistically not 
significant). Histopathological examination revealed that there was a marked stimulation 
of neo-angiogenesis in the MP group and ph VEGF group as compared to PLA-2 or the 
saline group. Capillary density score was : saline, 1.1 ± 1.0; PLA-2, 1.2 ± 1.0; MP, 2.0 ± 
0.9 (p<0.05 vs saline group) ph VEGF, 2.3 ± 1.1 (p<0,05 vs saline group). There was a 
marked inflammatory response in the injected muscles in the MP group. 
Conclusions : Metalloproteinase derived from venom of Indian cobra can lead to pro- 
found angiogenesis comparable to that produced by VEGF gene therapy. Further studies 
are warranted to confirm its efficacy and to evaluate the role of co-edministration with 
other angiogenic agents. 
